ANCOBON

LOE Approaching

flucytosine

NDAORALCAPSULEPriority Review
Approved
Nov 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. ANCOBON is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous…

Pharmacologic Class:

Nucleoside Analog Antifungal

Clinical Trials (4)

NCT06525389Phase 3Not Yet Recruiting

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Started Apr 2026
428 enrolled
Talaromycosis
NCT01562132Phase 2Terminated

Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection

Started Sep 2013
NCT00978107Phase 1Completed

Trial of TG4023 Combined With Flucytosine in Liver Tumors

Started Sep 2009
NCT00002113N/ACompleted

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

64 enrolled
Meningitis, CryptococcalHIV Infections